Evidence map›Paper›PMID 41280721›Full record

ArticleResearch (Washington, D.C.)2025

CCL26-CX3CR1 Axis Mediates a Feedback Loop between Cancer Cell and PMN-MDSCs to Promote CD8

Xiaotao Jiang, Hui Wu, Ning Yan, Anzhou Wu, Xianzhe Wang, Yi Wen, Jinqi An, Jingming Chen, Jiaxing Yan, Changlong Wang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiaotao JiangFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Hui WuFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Ning YanFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Anzhou WuFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Xianzhe WangFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Yi WenThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Jinqi AnFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Jingming ChenFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Jiaxing YanFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Changlong WangFirst Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Yushan ZouThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Yuancheng HuangDepartment of Oncology, Dongguan People's Hospital (The Tenth Affiliated Hospital of Southern Medical University), Dongguan 523000, Guangdong, China.
Wei WangLingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Peiwu LiDepartment of Hepatobiliary Diseases, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangzhou 510405, Guangdong, China.ORCID https://orcid.org/0000-0003-1300-1478
Kunhai ZhuangThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
Yufeng LiuCenter for Medical Research on Innovation and Translation, Guangzhou First People's Hospital, Guangzhou 510180, Guangdong, China.
Fengbin LiuThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of an immunosuppressive microenvironment is a critical factor in stomach carcinogenesis. Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) serve a pivotal function in mediating immune suppression. However, the precise mechanisms underlying PMN-MDSCs infiltration into the tumor immune microenvironment (TIME) and their immunosuppressive functions remain poorly understood. In this investigation, we observed that PMN-MDSCs were up-regulated during stomach carcinogenesis, with gastric cancer (GC) cells secreting CCL26 to promote the infiltration of PMN-MDSCs into the TIME via the CX3CR1 receptor. The infiltrating CX3CR1

Identifiers

PMID41280721
PMCPMC12635414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.